ONC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BeOne Medicines AG (ONC) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are positive catalysts such as anticipated sales growth for its blood cancer therapy and bullish analyst ratings, the technical indicators and financial performance suggest caution. The stock's MACD is negatively expanding, and the RSI shows no clear signal. Additionally, hedge funds are selling heavily, and the company's net income and EPS have significantly declined YoY. Given the investor's profile and the lack of strong proprietary trading signals, it is advisable to hold off on purchasing this stock for now.
The stock's MACD histogram is -2.336, below 0, and negatively expanding, indicating bearish momentum. The RSI is at 23.164, in the neutral zone, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 347.319, with key support at 325.457 and resistance at 369.181.
Analysts from Barclays and Morgan Stanley have raised price targets and maintain Overweight ratings.
Hedge funds are selling heavily, with a 7307.41% increase in selling activity last quarter. Financial performance shows a significant decline in net income (-202.88% YoY) and EPS (-188.89% YoY). MACD and RSI indicate no immediate bullish momentum.
In 2025/Q3, revenue increased by 41.00% YoY to $1.41 billion, but net income dropped by -202.88% YoY to $124.84 million. EPS also fell by -188.89% YoY to $0.08. Gross margin improved slightly to 86.09%, up 3.75% YoY.
Barclays raised the price target to $394 from $385, and Morgan Stanley raised it to $405 from $390, both maintaining Overweight ratings. Analysts are optimistic about the biotech sector's performance and BeOne Medicines' growth potential.
